News

Mutated forms of CLN3 protein may be involved in the abnormal activation of signals in brain cells that, in excess, could promote cell death, a study has found, which suggests that inhibiting these signaling cascades could represent a new therapeutic strategy to prevent the progression of the juvenile form of…

A team of Italian researchers suggests that CLN3 disease, also known as juvenile Batten disease, should be included in the differential diagnosis of people with autophagic vacuolar myopathy (AVM), after describing the case of a man who received an accurate diagnosis only after undergoing a muscle biopsy.

The activation of a recycling pathway, a process called autophagy, which leads to large storage vesicles in muscle cells, is a feature of all forms of juvenile Batten disease, a small study suggests. The study, “Autophagic vacuolar myopathy is a common feature of CLN3 disease,” was published in the …

Amicus Therapeutics is recruiting children for its new Phase 1/2 clinical trial that will assess the safety and efficacy of an investigational gene therapy for Batten disease caused by CLN3 gene mutations. The first child has completed a one-month observation period following dosing, with no reports of serious…

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…

New mutations have been found in PPT1 and TPP1, the two genes associated with neuronal ceroid lipofuscinoses type 1 and type 2 (NCL1 and NCL2), respectively, in a population of patients in India, researchers reported. Their study, “Batten disease: biochemical and molecular characterization revealing novel…

A type of Batten disease, called CLN8 disease, is associated with the failure of important cell- signaling molecules to properly interact and engage in critical signaling pathways, according to results of a recent study. The study, “Neuronal ceroid lipofuscinosis related ER membrane protein CLN8 regulates PP2A activity and ceramide levels,”…

Genetic mutations in the CLN8 gene block the transport of lysosomal enzymes to lysosomes, the cellular compartments that digest and recycle different types of molecules, directly contributing to the development of Batten disease, a study has found. The study, “CLN8 is an endoplasmic reticulum cargo receptor that regulates lysosome…

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Regenxbio’s one-time gene therapy RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease. Regenxbio expects to submit an Investigational New Drug (IND) application to the FDA…

Abeona Therapeutics has acquired the global rights to REGENXBIO’s proprietary NAV AAV9 delivery system to develop gene therapies for Sanfilippo syndrome type A (MPS IIIA) and type B (MPS IIIB). It also will be used for infantile (CLN1) and juvenile (CLN3) Batten disease. Both Sanfilippo…